Literature DB >> 22261638

Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke.

Mar Hernandez-Guillamon1, Pilar Delgado, Anna Penalba, David Rodriguez-Luna, Carlos A Molina, Alex Rovira, José Alvarez-Sabin, Mercè Boada, Joan Montaner.   

Abstract

BACKGROUND: Cerebral amyloid angiopathy (CAA) is one of the main causes of intracerebral hemorrhage (ICH) in the elderly.
OBJECTIVE: To analyze β-amyloid (Aβ) species in plasma in order to uncover biological markers that may contribute to improve the diagnosis of CAA in life.
METHODS: We determined the level of Aβ(1-40), Aβ(N-40), Aβ(1-42) and Aβ(N-42) in plasma of CAA-related ICH patients (n = 29) and healthy controls (n = 21) using xMAP® technology. Hemorrhages were identified and classified using a CT scan and brain MRI. Patients were clinically classified as probable or possible CAA according to the Boston criteria.
RESULTS: We found that plasma full-length Aβ(1-42) and truncated fragments Aβ(N-42) were higher in probable CAA patients than in controls (p < 0.001 and p = 0.046, respectively), and full-length Aβ(1-40) was selectively elevated in probable CAA compared to possible cases (p = 0.015) and controls (p = 0.005). In addition, plasma Aβ(N-42) levels were also higher in patients that presented multiple lobar macrohemorrhages compared to patients that had one symptomatic hemorrhagic event (p = 0.022), indicating that a certain degree of CAA severity is necessary to show increased Aβ fragments in peripheral circulation.
CONCLUSION: Our results suggest that specific Aβ fragments in plasma might be considered as potential biomarkers for the diagnosis of CAA.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261638     DOI: 10.1159/000333811

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  19 in total

1.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Recurrence of Lobar Hemorrhage: A Red Flag for Cerebral Amyloid Angiopathy-related Inflammation?

Authors:  Vaibhav Rastogi; Lauren L Donnangelo; Ganesh Asaithambi; Sharatchandra Bidari; Anna Y Khanna; Vishnumurthy Shushrutha Hedna
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

Review 3.  The Inflammatory Form of Cerebral Amyloid Angiopathy or "Cerebral Amyloid Angiopathy-Related Inflammation" (CAARI).

Authors:  Howard S Kirshner; Michael Bradshaw
Journal:  Curr Neurol Neurosci Rep       Date:  2015-08       Impact factor: 5.081

4.  Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.

Authors:  Stuart J McCarter; Timothy G Lesnick; Val J Lowe; Alejandro A Rabinstein; Scott A Przybelski; Alicia Algeciras-Schimnich; Vijay K Ramanan; Clifford R Jack; Ronald C Petersen; David S Knopman; Bradley F Boeve; Kejal Kantarci; Prashanthi Vemuri; Michelle M Mielke; Jonathan Graff-Radford
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 5.  The impact of cerebrovascular aging on vascular cognitive impairment and dementia.

Authors:  Tuo Yang; Yang Sun; Zhengyu Lu; Rehana K Leak; Feng Zhang
Journal:  Ageing Res Rev       Date:  2016-09-28       Impact factor: 10.895

Review 6.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

7.  ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy.

Authors:  Alex Montañola; Sofía Fernández de Retana; Antonio López-Rueda; Cristina Merino-Zamorano; Anna Penalba; Paula Fernández-Álvarez; David Rodríguez-Luna; Ana Malagelada; Francesc Pujadas; Joan Montaner; Mar Hernández-Guillamon
Journal:  Neuromolecular Med       Date:  2015-12-14       Impact factor: 3.843

8.  Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.

Authors:  Dimitri Renard; Giovanni Castelnovo; Anne Wacongne; Anne Le Floch; Eric Thouvenot; Julie Mas; Audrey Gabelle; Pierre Labauge; Sylvain Lehmann
Journal:  J Neurol       Date:  2012-05-11       Impact factor: 4.849

9.  Translating basic science research to clinical application: models and strategies for intracerebral hemorrhage.

Authors:  Christopher C Leonardo; Sean Robbins; Sylvain Doré
Journal:  Front Neurol       Date:  2012-05-29       Impact factor: 4.003

Review 10.  Outcome markers for clinical trials in cerebral amyloid angiopathy.

Authors:  Steven M Greenberg; Rustam Al-Shahi Salman; Geert Jan Biessels; Mark van Buchem; Charlotte Cordonnier; Jin-Moo Lee; Joan Montaner; Julie A Schneider; Eric E Smith; Meike Vernooij; David J Werring
Journal:  Lancet Neurol       Date:  2014-02-27       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.